Early effectiveness and safety analysis of belimumab in addition to standard treatment in patients with systemic lupus erythematosus.

Intravenous belimumab was well tolerated and significantly improved disease activity in Chinese patients with SLE at the early stage of treatment. More importantly, belimumab treatment could result in a rapid reduction in prednisone dose as early as week 12.